Hot Features
Ascendis Pharma A/S, operates as a biopharmaceutical company that focuses on developing TransCon-based therapies for unmet medical needs in Europe, the United States, and internationally. The company offers SKYTROFA for treating pediatric patients with growth hormone deficiency; and YORVIPATH, a onc... Ascendis Pharma A/S, operates as a biopharmaceutical company that focuses on developing TransCon-based therapies for unmet medical needs in Europe, the United States, and internationally. The company offers SKYTROFA for treating pediatric patients with growth hormone deficiency; and YORVIPATH, a once-daily subcutaneous injection for the treatment of adults with chronic hypoparathyroidism. It is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates. The company was incorporated in 2006 and is based in Hellerup, Denmark. Show more
| Période | Variation | Variation % | Ouver. | Haut | Bas | Moyenne Vol. Quot. | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | -17.16 | -7.27118644068 | 236 | 236 | 214.172 | 661283 | 220.25995676 | CS |
| 4 | -27.3 | -11.0912488827 | 246.14 | 250.27 | 214.172 | 555525 | 233.9370438 | CS |
| 12 | -11.92 | -5.16553995493 | 230.76 | 250.74 | 212.595 | 624190 | 231.75438795 | CS |
| 26 | 9.38 | 4.47818199179 | 209.46 | 250.74 | 192.28 | 674707 | 225.26124528 | CS |
| 52 | 45.12 | 25.9728298411 | 173.72 | 250.74 | 160.86 | 573079 | 211.79652411 | CS |
| 156 | 127.48 | 139.535901926 | 91.36 | 250.74 | 85.0801 | 486947 | 161.76855509 | CS |
| 260 | 89.14 | 68.7278334618 | 129.7 | 250.74 | 61.5791 | 462138 | 141.17228676 | CS |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales
Vous avez déjà un compte? Connexion
Vous n'avez pas de compte ? Inscription
En m'inscrivant, je confirme avoir lu, compris et accepté les Conditions générales d'ADVFN et j'affirme etre un investisseur privé.